Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy

Po Cheng Hung*, Huei Shyong Wang, Shao Hsuan Hsia, Alex M.C. Wong

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

5 Scopus citations


Stevens-Johnson syndrome (SJS) is a severe idiosyncratic reaction, most commonly triggered by medications, which is characterized by fever and mucocutaneous lesions, leading to necrosis and sloughing of the epidermis. Aside from skin and mucosal manifestations, SJS may also compromise heart, liver, kidney, lung, and gastrointestinal tract. Although cholestatic liver disease has been reported to occur in SJS, hepatic encephalopathy (HE) as a delayed complication has never been reported. We report a 4-year-old female child with anticonvulsant-induced SJS complicated by HE who was completely cured with a combination of systemic corticosteroid, intravenous immunoglobulin (IVIG), and plasmapheresis therapy. We suggested that plasmapheresis may be used as an adjuvant therapy for SJS with HE.

Original languageEnglish
Pages (from-to)356-358
Number of pages3
JournalBrain and Development
Issue number4
StatePublished - 04 2014


  • Child
  • Hepatic encephalopathy
  • Plasmapheresis
  • Stevens-Johnson


Dive into the research topics of 'Plasmapheresis as adjuvant therapy in Stevens-Johnson syndrome and hepatic encephalopathy'. Together they form a unique fingerprint.

Cite this